Special Issue

Resistance in Lung Cancer

Message from the Guest Editor

Despite significant advances in targeted therapies and immunotherapies, the emergence of drug resistance continues to be a major clinical challenge. Both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) exhibit diverse mechanisms of therapeutic resistance, ranging from genetic and epigenetic alterations to tumor–microenvironment interactions and adaptive cellular plasticity. Recent studies highlight novel approaches with which to overcome resistance, including next-generation targeted therapies, combination regimens, antibody–drug conjugates, and rationally designed immunotherapy strategies. While encouraging, these advances are still insufficient to establish comprehensive, long-term clinical guidelines.

In this context, we aim to explore the epidemiology, resistance mechanisms, tumor microenvironment, and emerging therapeutic strategies in drug-resistant lung cancer in this Special Issue. By keeping the scope broad, we welcome contributions that span basic mechanistic research, translational insights, and clinical perspectives, with particular emphasis on new directions and future opportunities to overcome resistance.

Guest Editor

Dr. Mohamed Gadelkarim

Department of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA

Deadline for manuscript submissions

15 March 2027

Cancers

mdpi.com/si/252251

mdpi.com/journal/
cancers

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)